Henry I. Miller
Henry I. Miller is an American medical researcher and columnist, formerly with the FDA, and from 1994 until 2018 the Robert Wesson Fellow in Scientific Philosophy and Public Policy at Stanford University's Hoover Institution, a public policy think tank located on the university's campus in California. He is an Adjunct Fellow of the Competitive Enterprise Institute. Career. He was educated at M.I.T. (B.S. in Life Sciences) and the University of California, San Diego (M.Sc. and M.D.) and was a resident and Clinical Fellow in Medicine at Harvard's Beth Israel Hospital in Boston. He performed  research on gene organization and expression as a Research Fellow in the laboratory of Philip Leder M.D. at the National Institutes of Health. Miller was a civil servant for fifteen years at the US Food and Drug Administration (FDA) (1979–94). He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and was instrumental in the rapid licensing of genetically engineered human insulin and human growth hormone. From 1985 to 1989, he was a special assistant to the FDA commissioner and from 1989 to 1993, the founding director of the FDA's Office of  Biotechnology. Since joining the Hoover Institution in 1994, Miller authored books and articles in scholarly journals, newspapers and online. He has been an Adjunct Fellow at the Competitive Enterprise Institute. He also has been a trustee of American Council on Science and Health. In 2017 it was reported that an article published (in 2015) on the Forbes website by Miller, under his own name, had been drafted by Monsanto. As reported by the New York Times, Monsanto asked Miller to write an article rebutting the findings of the International Agency for Research on Cancer that had classified glyphosate as "probably  carcinogenic to humans". He had indicated willingness “if I could start from a high-quality draft.” On discovering this, Forbes removed his blog from Forbes.com and ended their relationship with him. Positions. Tobacco-related debates. In a 1994 APCO Associates public relations strategy memo to help Phillip Morris organize a global campaign to fight tobacco regulations, Henry Miller was referred to as "a key supporter" and as a potential recruit. In 2012, in the context of arguing for harm reduction strategies, Miller wrote that "nicotine ... is not particularly bad for you in the amounts delivered by cigarettes or smokeless products . The vast majority of the health risks from tobacco come from the burning and inhalation of smoke. Quitting tobacco altogether remains the ideal outcome, but switching to lower-risk products would be a boon to the health of smokers." Mehmet Oz. In 2015, Miller coordinated a letter from a group of 10 physicians to Columbia University, demanding that Columbia's College of Physicians and Surgeons remove Mehmet Oz as a professor of surgery, alleging that Oz's public commentary on health issues had "misled and endangered" the public, and claiming that that Oz showed "disdain for science and for evidence -based medicine... for personal financial gain." Oz defended his work, said that he lacked conflicts of interest, and questioned the motivations of Miller and his other critics, saying that they had "have big ties to big industry." Columbia defended Oz, citing the principle of academic freedom and faculty members' freedom of expression. Selected publications. Books Research articles Articles and Op-Eds He is a columnist for "Project Syndicate," which translates his articles into as many as 12 languages and submits them to its syndicate of more than 500 newspapers and other publications. Miller regularly appears on the nationally syndicated radio  programs of John Batchelor and Lars Larson. Awards. Described as a "vocal proponent of the free market", he was shortlisted in 2006 (in the Society and ethics category) by the editors of "Nature Biotechnology" as one of the people who had made the "most significant contributions" to biotechnology during the previous decade.